Grade: Pharmaceutical Grade

Factory Location: Quanzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Payment Terms: L/C

Rivaroxaban is a new type of oral anticoagulant drug used in adult patients with non-valvular atrial fibrillation (excluding atrial fibrillation caused by rheumatic valvular heart disease and atrial fibrillation that occurs after heart valve replacement surgery) to reduce the risk of stroke and systemic embolism